Taken together, these data support a role for targeting mGlu5 in early stages of AD, perhaps in combination with the current standard of care (i.e., acetylcholinesterase inhibitors) to slow disease progression and/or improve the treatment response to the standard of care. The gene discussed is GRM5; the disease is Alzheimer disease.